Avaliação da qualidade de vida de pacientes com hidradenite supurativa em
                        uso de adalimumabe: estudo-piloto

Ximenes, Bárbara Álvares Salum; Fleury, Luiz Fernando Fróes; Terra, Taiane Medeiros; Ribeiro, Ana Maria Quinteiro; Junqueira, Rafael Ferreira; Freire, Alexandra Sousa; Miranda, Flávia Tandaya Grandi; Peres, Marina Dumont Palmerston

doi:10.5935/scd1984-8773.20191131240

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 4640 articles were retrieved, 194 articles were screened and 70 were used in the qualitative analysis. 1 – 18 , 21 – 66 Of these, 12 articles were from Brazil. 1 , 56 – 66 …”

Section: Resultsmentioning

confidence: 99%

“…Because of the profound impact on HRQoL, the use of patient-reported outcomes, such as Dermatology Life Quality Index, is considered essential in the management of HS as well as of pain and pruritus. 2 , 4 , 6 , 7 , 38 , 62 , 66 …”

Section: Resultsmentioning

confidence: 99%

“…Adalimumab, a recombinant human TNF inhibitor, is the only approved biologic agent indicated for the treatment of moderate-to-severe HS unresponsive or intolerant to oral antibiotics. 5 , 9 , 18 , 22 , 27 , 39 – 43 , 59 , 61 , 66 Long-term use is needed to maintain control of manifestations; safety and efficacy profile of long-term adalimumab is documented. 67 – 70 …”

Section: Resultsmentioning

confidence: 99%

“…Frequently associated comorbidities include obesity, metabolic syndrome, hormonal disorders, smoking, pyoderma gangrenosum and arthritis; all these conditions should be properly assessed and managed. 1 , 2 , 6 , 7 , 29 , 37 , 39 , 66 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil

Machado¹,

Magalhães²,

Silva³

et al. 2022

DIC

View full text Add to dashboard Cite

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

show abstract

“…Overall, 4640 articles were retrieved, 194 articles were screened and 70 were used in the qualitative analysis. 1 – 18 , 21 – 66 Of these, 12 articles were from Brazil. 1 , 56 – 66 …”

Section: Resultsmentioning

confidence: 99%